Astrazeneca covid-19 vaccine development

Other Transaction IDV Awarded Last action

Contract number
W15QKN2191003
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order
Not on record
IDV ceiling
$857,061,969.19
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Set-aside
No set-aside
Competition
Only One Source
Pricing
Other

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement (OTA) to AstraZeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer, on October 28, 2020. The award has a potential value of $857,061,969.19 and is focused on the development of AstraZeneca's COVID-19 vaccine.

AstraZeneca has a history of providing a range of pharmaceutical products and medical countermeasures to federal agencies, including influenza vaccines, COVID-19 treatments, monoclonal antibodies, and other pharmaceuticals to the Department of Health and Human Services, Department of Defense, and Department of Veterans Affairs. The company also holds several federal Indefinite Delivery Vehicles (IDVs) for pharmaceutical products with agencies such as the Centers for Disease Control and Prevention and the Department of Veterans Affairs, which have been used to procure influenza vaccines and other medical countermeasures.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00013 · Agreement closeout $0
Funding Only Action P00012 · Deobligate BLA milestones -$351,871,845
Supplemental Agreement for work within scope P00011 · Destruction of doses $0
Supplemental Agreement for work within scope P00010 · The purpose of this MOD is to restart manufacturing and restructure MS tables based on the move from emergent $0
Supplemental Agreement for work within scope P00006 · The purpose of this modification is to extend rest time frame by 30 days and remove the hrpas rating from the agreement. $0
Supplemental Agreement for work within scope P00005 · The purpose of this modification is to definitize UPA modification P00003. $0
Supplemental Agreement for work within scope P00004 · The purpose of this modification is to extend the restart timeframe by 30 days. $0
Supplemental Agreement for work within scope P00003 · The purpose of this modification is to issue an undefinitized modification to cease manufacture and testing of AZ drug substance at emergent biosolutions. $0
Supplemental Agreement for work within scope P00002 · The purpose of this modification is to provide direction to astrazeneca direction to delay the delivery of doses to the USG, so that AZ can provide such doses… $0
Supplemental Agreement for work within scope P00001 · Agreement definitization $0
Original award $1,208,933,814
Show all 11

Quick answers

Who was awarded contract W15QKN2191003?

W15QKN2191003 was awarded to Astrazeneca Pharmaceuticals LP by ACC Picatinny (Army Contracting Command) on October 28, 2020.

How much is contract W15QKN2191003 worth?

W15QKN2191003's own ceiling is $857,061,969.

Which agency awarded contract W15QKN2191003?

ACC Picatinny (Army Contracting Command) awarded W15QKN2191003, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login